Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363358 · ClinicalTrials.gov registry record
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 6,086
- Enrollment target
NCT05363358 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 6,086 participants.
The verdict
NCT05363358 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 6,086 participants
- Enrollment target
Study Summary
The main aim of this study is to evaluate the rates of adverse events of special interest (AESIs) (thrombotic events, acute kidney injury \[AKI\], and hemolytic events) among participants with CIDP initiating GGL compared with rates among participants with CIDP initiating comparator intravenous immunoglobulin (IVIG) products. No study medicines will be provided to participants in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,086 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2022-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363358
The ClinicalTrials.gov registry entry for NCT05363358 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,086 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05363358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363358 about?
NCT05363358 is a clinical study titled "A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)". The main aim of this study is to evaluate the rates of adverse events of special interest (AESIs) (thrombotic events, acute kidney injury \[AKI\], and hemolytic events) among participants with CIDP initiating GGL compared with rates among participants with CIDP initiating comparator intravenous immu...
What is the current status of trial NCT05363358?
This trial is currently completed. The enrollment target is 6,086 participants. The study started on 2022-05-27. Estimated completion is 2022-12-01.
Who is sponsoring clinical trial NCT05363358?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.